Publications by authors named "Kausik Ray"

Claim this Profile
E
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease.
Michael H Davidson, Michael Szarek, Philip Scheltens, Everard Vijverberg, Andrew Hsieh, Kausik K Ray

J Prev Alzheimers Dis· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral triple combination lipid-lowering therapy and LDL cholesterol goal attainment: A simulation using the SANTORINI study cohort.
Julius L Katzmann, Kausik K Ray, Ben Lee, Christian Becker, Konstantin Articus

Eur J Prev Cardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Obicetrapib Across the Spectrum of Background Lipid-Lowering Therapies: Pooled Analyses of the BROADWAY and BROOKLYN Randomized Trials.
Fotios Barkas, Michael Szarek, Adam J Nelson, Marc Ditmarsch, Douglas Kling, Kausik K Ray

Eur J Prev Cardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipoprotein(a) Levels and Time to Cardiovascular Benefit With Alirocumab in Patients With Recent Acute Coronary Syndrome.
Kausik K Ray, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Sergio Fazio

J Am Coll Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Uric Acid-Lowering Therapies on Gout Frequency with Bempedoic Acid: Clinical Insights From CLEAR Outcomes.
Kausik K Ray, Stephen J Nicholls, A Michael Lincoff, Na Li, Heather A Powell

JACC Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Great debate: fire-and-forget beats personalized lipid-lowering treatment.
Lale Tokgozoglu, Fotios Barkas, Kausik K Ray, Eugenia Gianos

Eur Heart J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anxiety and depression and secondary prevention of coronary heart disease in 14 countries across six WHO regions: the INTERASPIRE study.
Chantal F Ski, Catriona S Jennings, Dirk De Bacquer, Kornelia Kotseva, John William McEvoy, Kausik K Ray

Eur J Prev Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corneal arcus and Achilles tendon thickness reflect circulating lipoprotein(a) levels in familial hypercholesterolemia: Implication for predicting future cardiovascular events.
Kota Murai, Yu Kataoka, Kausik K Ray, Sayaka Funabashi, Mika Hori

J Clin Lipidol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipid-lowering therapy and LDL cholesterol control among high- and very high-risk patients in Portugal: An analysis of the SANTORINI study.
Carlos Aguiar, Patrício Aguiar, João Sequeira Duarte, Victor Gil, Jorge Mimoso, Kausik K Ray

Rev Port Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JCL roundtable: European perspective on comprehensive lipid management and cardiovascular health.
Børge G Nordestgaard, Kausik K Ray, P Barton Duell

J Clin Lipidol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidemias - Advancing evidence-based care through innovation.
Florian Kronenberg, Jan Borén, Kausik K Ray

Atherosclerosis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients: A Pooled Analysis.
Stephen J Nicholls, Adam J Nelson, Kausik K Ray, Christie M Ballantyne, Marc Ditmarsch

J Am Coll Cardiol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated with Elevated High-Sensitivity C-Reactive Protein Levels in Individuals with Atherosclerotic Cardiovascular Disease in the US and the UK.
Kausik K Ray, Simon Bertram Reuter, Aysegul Dalbeler, Mads D Faurby, Gasper Letnar

Eur J Prev Cardiol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lp(a) testing for the primary prevention of cardiovascular disease in high-income countries: a cost-effectiveness analysis.
Jedidiah I Morton, Florian Kronenberg, Magdalena Daccord, Nicola Bedlington, Marius Geanta, Kausik K Ray

Atherosclerosis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in achieving LDL-C goals: Insights from the Italian SANTORINI study cohort.
Marcello Arca, Paolo Calabrò, Anna Solini, Angela Pirillo, Rosanna Gambacurta, Kausik K Ray

Nutr Metab Cardiovasc Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipid-lowering therapy treatment regimens in high- and very high-risk patients for the prevention of cardiovascular events: results from the Irish cohort of the multinational, observational SANTORINI study.
Himanshu Rai, John Joseph Coughlan, Daniel O'Callaghan, Richard Sheahan, Ross Murphy, Kausik K Ray

Ir J Med Sci· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. Reply.
Stephen J Nicholls, Adam J Nelson, Kausik K Ray

N Engl J Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiac Rehabilitation in Patients with Coronary Heart Disease - Provision, Attendance, and Outcomes: Results from the INTERASPIRE Survey from Fourteen Countries Across Six WHO Regions.
Kornelia Kotseva, Dirk De Bacquer, Catriona Jennings, John William McEvoy, Lars Ryden, Kausik K Ray

Glob Heart· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination lipid-lowering strategies after acute coronary syndrome: reconsidering cholesterol targets.
Paola Gargiulo, Kausik K Ray, Pasquale Perrone-Filardi

Eur Heart J· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global detection and management of dysglycaemic patients with coronary artery disease results from the INTERASPIRE survey from 14 countries across six WHO regions.
Safi Moayad Al-Azzawy, John William McEvoy, Isabelle Johansson, Agnieszka Adamska, Guy De Backer, Kausik K Ray

Cardiovasc Diabetol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study.
Julia Brandts, Fotios Barkas, Dirk De Bacquer, Catriona Jennings, Guy G De Backer, Kausik K Ray

Eur J Prev Cardiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Bempedoic Acid in High Cardiovascular Risk Patients with Statin Intolerance: An Analysis of the CLEAR Outcomes Trial.
Stephen J Nicholls, Kausik K Ray, A Michael Lincoff, Evelyn Sarnes, Kristin K Gillard

Am J Cardiovasc Drugs· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient perceptions on lipoprotein(a) testing and treatment for secondary prevention of cardiovascular disease: results from the INTERASPIRE study in seven countries across five World Health Organization regions.
Catriona Sian Jennings, Eanna Kenny, Dirk De Bacquer, Jaimini Cegla, Kausik Kumar Ray

Eur J Cardiovasc Nurs· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physician perspectives on Lp(a) testing and management in patients with cardiovascular disease: interviews from seven countries across five world health organization regions from INTERASPIRE.
Jaimini Cegla, Catriona Jennings, Eanna Kenny, Dirk De Bacquer, Kausik Kumar Ray

Eur J Prev Cardiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing familial hypercholesterolaemia management: real-world evidence for inclisiran's impact on LDL-C and arterial stiffness.
Amany Elshorbagy, Kausik K Ray

Prog Cardiovasc Dis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis